Item 4. Purpose of Transaction.
Item 4 of the Initial Schedule 13D is hereby amended and supplemented by adding the following at the end of Item 4 of the Initial Schedule 13D:
Secondary Offering
On April 12, 2022, in connection with a registered secondary public offering (the “Secondary Offering”) of Common Stock, the CCMP Investors entered into an underwriting agreement (the “Underwriting Agreement”) with the Company, Jefferies LLC and Robert W. Baird & Co. Incorporated, as representatives of the several underwriters listed on Schedule II thereto (the “Underwriters”), and the other selling stockholders listed on Schedule I thereto (together with the CCMP Investors, the “Selling Shareholders”). Pursuant to the Underwriting Agreement, the CCMP Investors agreed to sell to the Underwriters, and the Underwriters agreed to purchase from the CCMP Investors, subject to and upon the terms and conditions set forth therein, 12,347,733 shares of Common Stock, inclusive of the full exercise of the Underwriters’ 30-day over-allotment option, at a price of $10.00 per share, less underwriting discounts and commissions. The Secondary Offering, including the full exercise of the over-allotment option, closed on April 18, 2022.
In connection with the Secondary Offering, each of the Selling Shareholders entered into a lock-up agreement (the “Lock-up Agreement”) with the Underwriters. Under the Lock-up Agreement, each Selling Shareholder agreed, subject to certain exceptions, not to offer, sell, pledge or otherwise transfer any shares of Common Stock for 90 days after April 12, 2022.
The foregoing descriptions of the Underwriting Agreement and Lock-up Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement, which includes the form of Lock-up Agreement as an exhibit, and which is incorporated by reference to Item 7.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Initial Schedule 13D is hereby amended and restated to read as follows:
The information set forth in Items 2, 3 and 4 is hereby incorporated by reference into this Item 5.
(a) The aggregate number of shares of Common Stock and the percentage of total outstanding shares of Common Stock beneficially owned by the Reporting Persons is set forth below. References to percentage ownerships of shares of Common Stock in this Statement are based upon the 194,186,576 shares of Common Stock stated to be outstanding as of April 6, 2022 in the Company’s prospectus supplement filed with the Securities and Exchange Commission on April 13, 2022. The Reporting Persons may be deemed to beneficially own an aggregate of 59,605,000 shares of Common Stock, which constitutes approximately 30.7% of the Company’s Common Stock, calculated in accordance with Rule 13d-3 under the Act. The filing of this Statement shall not be construed as an admission that a Reporting Person beneficially owns those shares held by any other Reporting Person.
CCMP Co-Invest may be deemed to beneficially own 13,845,149 shares of Common Stock, which represents approximately 7.1% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP Capital Investors may be deemed to beneficially own 43,169,993 shares of Common Stock, which represents approximately 22.2% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP Capital Investors (Employee) may be deemed to beneficially own 2,589,858 shares of Common Stock, which represents approximately 1.3% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP Co-Invest GP, as the general partner of CCMP Co-Invest, may be deemed to beneficially own 13,845,149 shares of Common Stock, which represents approximately 7.1% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP Capital Associates, as the general partner of each of CCMP Capital Investors and CCMP Employee, may be deemed to beneficially own an aggregate of 45,759,851 shares of Common Stock, which represents approximately 23.6% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP Capital Associates GP, as the general partner of CCMP Capital Associates, may be deemed to beneficially own an aggregate of 45,759,851 shares of Common Stock, which represents approximately 23.6% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP, as the owner of each of CCMP Capital Associates GP and CCMP Co-Invest GP, may be deemed to beneficially own an aggregate of 59,605,000 shares of Common Stock, which represents approximately 30.7% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.
CCMP GP, as the general partner of CCMP, may be deemed to beneficially own an aggregate of 59,605,000 shares of Common Stock, which represents approximately 30.7% of the outstanding shares of Common Stock calculated in accordance with the requirements of Rule 13d-3 under the Act.